Effects of anti-asthma therapy on dyspnea perception in acute asthma patients  by Choi, Inseon S. et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 855–861KEYWORD
Acute;
Asthma;
Dyspnea;
Perception
Treatment
0954-6111/$ - s
doi:10.1016/j.r
Correspondi
Chonnam Nati
Gwangju 501-7
fax: +82 62 225
E-mail addrEffects of anti-asthma therapy on dyspnea
perception in acute asthma patients
Inseon S. Choia,, Se-Woong Chunga, Eu-Ryeong Hana, Jeong-Hwan Lima,
Jeong-Seon Choa, Yoon-Cheol Leea, Seok Choa, An-Soo JangbaDepartment of Allergy, Chonnam National University Medical School and Research Institute of Medical
Sciences, Gwangju, Republic of Korea
bDepartment of Internal Medicine, Soonchunhyang University Hospital, Bucheon, Republic of Korea
Received 16 January 2005; accepted 27 August 2005S
;
ee front matter & 2005
med.2005.08.021
ng author. Departmen
onal University Hospit
57, Korea. Tel.: +82 62
8578.
ess: ischoi@chonnam.chSummary Blunted perception of dyspnea may predispose patients to fatal asthma
attacks. To examine whether this impaired perception of dyspnea in patients with
acute asthma could be corrected by anti-asthma therapy, the medical records of 104
consecutive asthma patients who had been hospitalized as a result of asthma attacks
were analyzed retrospectively. During the course of treatment with conventional
asthma medications, the forced expiratory volume in 1 s (FEV1) and the Borg scale-
based dyspnea perception scores during breathing through an inspiratory muscle
trainer were measured at least twice. The baseline Borg score measured just before
discharge was significantly lower than from that measured initially, regardless of
improvement in FEV1. In contrast, the Borg score at the highest resistance (HR;
3.1270.26 vs. 5.0370.53; Po0.01) and the HR-induced DBorg score (1.6870.20 vs.
4.4770.54, Po0.001) were increased significantly in the Poor Perceivers (Borg score
p 5 at HR and HR-induced DBorg score p3). Patient age (r ¼ 0.363, Po0.001),
blood eosinophil counts (r ¼ 0.285, Po0.01), and serum total IgE levels
(r ¼ 0.213, Po0.05), but not FEV1, were significantly related to the effect of
the treatment on the HR-induced DBorg scores. These findings suggest that anti-
asthma treatments decrease dyspnea even without a concomitant improvement in
lung function and correct the impaired perception of inspiratory resistive load in
acute asthma, and that age and allergy influence the effect of treatment on
impaired perception.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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220 6571;
onnam.ac.kr (I.S. Choi).Introduction
Kikuchi et al.1 showed that asthma patients
who experienced near-fatal attacks had reduceded.
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tion of dyspnea, and they suggested that these
impairments might predispose these patients to
fatal asthma attacks. Impaired perception of
dyspnea has been correlated with asthma severity
based on values of baseline forced expiratory
volume in 1 s (FEV1),
2 airway hyperresponsiveness,2
and eosinophilic airway inflammation.3 Moreover,
we previously demonstrated that short-acting
inhaled b2 agonist treatment increases the percep-
tion of dyspnea induced by a resistive load in
patients with asthma,4 and other investigators have
shown that treatment with an inhaled corticoster-
oid for 8 weeks or longer enhances the perception
of dyspnea during breathing through resistance5
and of histamine-induced airway narrowing in
asthma.6 Therefore, it is possible that the impaired
perception of dyspnea in asthma is the result of
underlying severe disease, even if under-treatment
or delayed treatment owing to poor perception of
dyspnea exacerbates the disease.
The impaired perception of dyspnea may affect
the clinical course of asthma to a greater extent
during asthma attacks than during the stable
chronic state. Nonetheless, no study has directly
investigated the impairment of dyspnea perception
that occurs during acute asthma. The aims of this
study were to determine whether the impaired
perception of dyspnea in patients with acute
asthma could be corrected by anti-asthma therapy,
and to explore the factors that contribute to the
effects of the treatment.Methods
Subjects
A total of 115 records of 104 consecutive patients
with acute asthma were studied. These patients
were hospitalized at Chonnam National University
Hospital, Gwangju, Korea, between August 2003
and December 2004 as a result of asthma attacks
(94 patients had been hospitalized once, 9 twice,
and 1 three times); they performed resistive load-
induced dyspnea perception tests at least two
times during the period of hospitalization, and
the data were analyzed retrospectively. The diag-
nosis of asthma was based on an improvement in
FEV1 ofX12% and at least 200mL after anti-asthma
treatment or a diurnal variability of peak expira-
tory flow (PEF) ofX20% during hospitalization. The
severity of asthma exacerbation was classified
according to the updated 2004 workshop report
by the Global Initiative for Asthma.7 The Institu-tional Review Board of Chonnam National Univer-
sity Hospital approved this study, and all the
patients were informed of the experimental pro-
cedures and provided written informed consent.Lung function tests
FEV1 was measured upon presentation, at 1 and 3 h
after the initial treatment, and every morning upon
rising until discharge from the hospital using a
Fleisch Pneumotachograph (Spiro Analyzer ST-250;
Fukuda Sangyo, Tokyo, Japan). Each patient per-
formed the tests according to the standards
developed by the American Thoracic Society.8 All
patients showed a reduced ratio of FEV1/forced
vital capacity (i.e., o70%) at least once during
hospitalization, which indicates obstruction to the
flow of air from the lungs. The regression equation
developed by Crapo et al.9 was used for the
predicted values of FEV1. Patients who showed a
significant improvement (X12% and at least
200mL) in the morning FEV1 value at the time of
the last perception test as compared to the first
were defined as ‘‘Gradual Improvers’’, while the
others were designated as ‘‘No Further Improvers’’.Dyspnea perception scoring
The perception of dyspnea during resistive loading
was measured with the use of an inspiratory muscle
trainer (cat no. 22-7500DHM; Diemolding Health-
care Division, Canastota, NY) as previously de-
scribed.4 The sensation of dyspnea was measured
while the subject breathed through the inspiratory
muscle trainer with linear inspiratory resistances of
the control (resistive load of 0), and with resistor
diameters of 7 (1), 6 (2), 5 (3), 4 (4), 3 (5), and 2
(6)mm. After breathing for 1min at each level of
resistance, the subject scored the sensation of
dyspnea using the modified Borg scale, which is a
linear scale that ranks the magnitude of difficulty in
breathing within a range of 0 (none) to 10
(maximal). Immediately after the morning FEV1
was measured, the perception of dyspnea was
scored on the Borg scale during breathing through
the inspiratory muscle trainer. The scoring of
perception of dyspnea was performed at least
twice, soon after admission and just before
discharge. Because the lower limit within the 95%
confidence interval (mean—standard deviation 
1.65) of the Borg score at the highest resistive load
of 6 (HR) in healthy control subjects was 5.3 in a
previous study,4 a member of the ‘‘Poor Perceiver’’
group was defined arbitrarily as a person who
had a Borg score of p5 at HR, and an HR-induced
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Table 1 Clinical characteristics of patients with acute asthma who showed a significant (Gradual Improver) or
no (No Further Improver) improvement in the morning forced expiratory volume in 1 s (FEV1), which was obtained
when the final and initial Borg scores were compared.
Gradual Improver No Further Improver
(n ¼ 52) (n ¼ 63)
Age (years) 57.972.0 61.372.1
Men/Women 22/30 24/39
Smoking (current/ex/none) 15/10/25 10/17/31
Asthma duration (years) 6.971.4 8.271.2
Blood eosinophils(/mm3) 439787 4237102
Log total IgE 2.2170.09 2.2470.10
(Geometric mean, IU/mL) (162) (175)
FEV1 (% pred) at visit 39.872.7 47.672.7

At 1st Borg score 47.273.0 61.073.1
At mid-Borg score 63.573.6 58.073.1
At last Borg score 71.172.9 58.573.1
At discharge 70.073.3 61.873.1
Attack severity (1/2/3/4)# 2/9/38/3 6/17/38/2
# 1: mild, 2: moderate, 3: severe, 4: respiratory arrest imminent.
Po0.05.
Po0.01.
Effects of therapy on dyspnea perception in acute asthma 857Borg score that differed from the baseline value
(DBorg score) by p3. The others were defined as
‘‘Fair Perceivers’’. Boulet et al.10 defined ‘‘hypo-
perceiver’’ as a person with a DBorg score at 20%
fall in FEV1p1, and Kikuchi et al.1 reported that
the mean Borg score during breathing with a
resistance of 30 cm of water per liter per second
for patients with near-fatal asthma was about 2.
Although we did not examine whether the resis-
tance of the 2-mm-diameter load in this study was
comparable with the resistance in previous stu-
dies,1,10 we believe that the adoption of a DBorg
score p3 for the definition of ‘‘Poor Perceiver’’
would make this definition approximate the
others.1,10 For a stricter definition, a person who
had a Borg score of p3 at HR, and an HR-induced
DBorg score of p2 was defined as a ‘‘Very Poor
Perceiver’’.Statistical analysis
All data were analyzed using SPSS version 12.0 for
Windows. The results are expressed as mean7SE.
Differences between groups were analyzed using
Student’s t-test and w2-tests. Lung function and
dyspnea scores were compared using the repeated
measures analysis of variance (ANOVA) with a
Bonferroni correction. Pearson’s correlations were
used to assess the relationships between variables,
and a P-value ofo0.05 was considered to be
statistically significant.Results
Subject characteristics, including demographics
and asthma attack severity, are presented in
Table 1. The subjects ranged in age from 19 to 85
years. The FEV1 values in not only the Gradual
Improver (N ¼ 52) but also the No Further Improver
groups (N ¼ 63) increased significantly in terms of
the first Borg scores, compared with the values on
presentation (No Further Improvers: 47.672.7% vs.
61.073.1%, Po0.001; Fig. 1). The FEV1 values
upon presentation and at first Borg measu-
rement were significantly lower, but at last
measurement significantly higher in Gradual Im-
provers than in No Further Improvers. However, the
mean number of days of hospitalization during
which the measurements were performed did not
differ significantly between the groups (first: 2.0
vs. 2.8 days; middle: 6.5 vs.7.4 days; last: 11.2 vs.
11.5 days).
In the Gradual Improver group, as lung function
increased gradually, the baseline Borg score with-
out resistive load decreased gradually (mean:
1.1370.20-0.8270.18-0.5170.15; Fig. 1). Sur-
prisingly, in the No Further Improver group, even
though the FEV1 value at the last measurement was
not significantly altered from that at the first
measurement, the baseline Borg score also de-
creased gradually (1.3870.26-0.8370.17-
0.5270.12). However, the Borg scores and DBorg
scores at HR for both groups were not significantly
altered during the treatment period.
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Figure 1 Changes in lung function and dyspnea during therapy for acute asthma. Subjects who showed a significant
increase in the morning FEV1, which was obtained when the final and initial Borg scores were compared, were classified
as ‘‘Gradual Improvers’’, and the remaining patients were designated as ‘‘No Further Improver’’. K: baseline Borg
score; J: Borg score when the highest inspiratory resistive load was applied; D: the highest load-induced score
difference from the baseline. # # Po0.01, # # # Po0.001: compared with the value at admission. ** Po0.01,
*** Po0.001: compared with the value at the initial Borg score.
Table 2 Clinical characteristics of acute asthma patients with or without impaired perception of dyspnea.
Poor Perceiver
(n ¼ 34)
Fair Perceiver
(n ¼ 81)
Very Poor
Perceiver
(n ¼ 14)
The Others
(n ¼ 101)
Age (years) 64.872.4 57.771.8 67.472.2 58.771.6
Men/Women 10/24 36/45 4/10 42/59
Smoking (current/ex/none) 4/11/17 21/16/39 2/3/9 23/24/47
Asthma duration (years) 7.771.5 7.571.1 3.971.1 8.171.0
Blood eosinophils(/mm3) 4697128 414781 5337255 416769
Log total IgE 2.0970.12 2.2970.08 1.9770.12 2.2770.07
(Geometric mean, IU/mL) (123) (194) (94) (185)
FEV1 (% pred) at visit 51.173.4 41.172.3
 52.075.4 43.072.1
At 1st Borg score 61.573.2 51.972.8 58.875.8 54.272.4
At mid Borg score 69.074.5 56.972.7 71.978.1 59.072.4
At last Borg score 71.874.0 61.072.6 70.876.5 63.372.4
At discharge 70.974.4 63.372.7 65.677.2 65.672.4
Attack severity (1/2/3/4)# 3/11/19/1 5/15/57/4 1/5/8/0 7/21/68/5
Poor or Fair Perceivers: the patients with highest resistive load (HR) -induced Borg scores of p5, and with scores that were
different from the baseline (DBorg scores) by p3, or the remaining patients; Very Poor Perceivers or The Others: the patients
with HR-induced Borg scores ofp3, and with DBorg scoresp2, or the remaining pateints. # 1: mild, 2: moderate, 3: severe, 4:
respiratory arrest imminent.
Po0.05.
Po0.01.
I.S. Choi et al.858There were 34 ‘‘Poor Perceiver’’ patients
(Table 2). Poor Perceivers were significantly older
and had higher FEV1 values, except at discharge,
than did the other patients (Fair Perceivers). The
mean number of days of hospitalization did not
differ significantly between the groups (first: 2.1
vs. 2.6 days; middle: 6.2 vs.7.3 days; last: 10.3 vs.11.8 days). Both Poor Perceivers and Fair Perceivers
showed progressive improvement in FEV1 during
hospitalization (Fig. 2A). In the Poor Perceiver
group, as lung function increased gradually, the
Borg scores and the DBorg scores at HR also
increased gradually (Borg score: 3.1270.26-
4.0870.38-5.0370.53; DBorg score: 1.6870.20-
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Figure 2 Changes in lung function and dyspnea during therapy for acute asthma. Panel A: Patients who had the highest
resistive load (HR) -induced Borg scores of p5, and scores that differed from the baseline (DBorg scores) by p3 were
defined as ‘‘Poor Perceivers’’, and the remaining patients were designated as ‘‘Fair Perceivers’’. Panel B: Patients who
had the HR -induced Borg scores of p3, and the DBorg scores p2 were defined as ‘‘Very Poor Perceivers’’, and the
remaining patients were designated as ‘‘The Others’’.K: baseline Borg score; J: Borg score when the HR was applied;
D: the DBorg scores. # # Po0.01, # # # Po0.001: compared with the value at admission. * Po0.05, ** Po0.01,
*** Po0.001: compared with the value at the initial Borg score.
Effects of therapy on dyspnea perception in acute asthma 8592.8970.40-4.4770.54), while the baseline Borg
scores decreased gradually (1.4470.24-1.187
0.24-0.5670.18). In the Fair Perceiver group, as
lung function increased gradually, the baseline Borg
scores also decreased gradually (1.1970.22-
0.6670.13-0.4970.11). In contrast to Poor Percei-
vers, the Borg scores at HR in Fair Perceivers
decreased gradually (7.3570.24-6.6870.26-
6.2370.26). However, the HR-induced DBorg scores
were not significantly altered.
There were only 14 ‘‘Very Poor Perceiver’’
patients (Table 2). Many comparisons were statis-
tically insignificant, probably because of the small
number of subjects. However, Very Poor Perceivers
were significantly older and had a shorter duration
of asthma and a lower level of serum total IgE than
did the other patients. In the Very Poor Perceiver
group, as lung function increased gradually, albeit
insignificantly, the Borg scores changed in a manner
similar to those in Poor Perceivers. The gradual
increase in DBorg scores at HR was statistically
significant (0.7570.23-2.4370.75-3.3570.78;
Fig. 2B).
Ten patients had been hospitalized two or more
times. Of these, four patients were Poor Percei-
vers; however, except for one patient, all had been
classified as ‘‘Fair Perceivers’’ during another
hospitalization.The first baseline Borg scores and the first HR-
induced DBorg scores were significantly correlated
with age (Table 3). The change in HR-induced DBorg
scores from the first to the last measurement was
also significantly correlated with age. The blood
eosinophil counts and the serum total IgE levels
showed significant negative correlations with the
change in the HR-induced DBorg score after
treatment. However, the post-treatment FEV1
change was not correlated with the DBorg score
change in all subjects, or in the Poor Perceiver
group.Discussion
In this study, conventional anti-asthma treatment
increased the perception of inspiratory resistive
load in acute asthma. As reported previously in
studies showing enhanced perception of dyspnea by
asthma patients at an outpatient clinic, following
treatment with short-acting inhaled b2 agonist
4 or
inhaled corticosteroid,5,6,11,12 anti-asthma medica-
tions (here, inhaled b2 agonist and corticosteroids)
corrected the impaired perception of dyspnea in
many patients who were hospitalized as a result of
an asthma attack. Poor perception in asthma may
lead to a delay in treatment, which is probably one
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Table 3 Relationship between the degrees of dyspnea (expressed as Borg scores) and the clinical characteristics
of the patients with acute asthma.
Degree of dyspnea
At first Change after treatment
Without load With load Without load With load
Age 0.214 0.282 0.175 0.363
Smoking 0.063 0.028 0.019 0.012
Asthma duration 0.013 0.023 0.059 0.086
Blood eosinophils 0.055 0.107 0.170 0.285
Serum total IgE 0.090 0.235 0.058 0.213
FEV1 0.020 0.276 0.052 0.174
DFEV1 after treatment 0.128 0.174 0.096 0.112
Attack severity 0.000 0.211 0.043 0.086
Change after treatment: the difference between the first and the last measurements during asthma treatment; Load: the
highest inspiratory resistive load.
Po0.05.
Po0.01.
Po0.001.
I.S. Choi et al.860of the contributory factors to mortality associated
with asthma.13 Therefore, perception impairment
and its correction should be emphasized, especially
in patients with acute asthma. In a follow-up of
more than 2 years, Ruffin et al.14 reported that
blunted perception of breathlessness in patients
who had had near-fatal asthma attacks had been
normalized to the point that it was no different
from that of other asthmatic subjects, as airway
responsiveness became milder. This impaired per-
ception seems to be corrected by treatment, not
only in patients with near-fatal asthma, which is
relatively rare, but also in more typical patients
who are hospitalized as a result of an asthma
attack.
Similar to a report showing that elderly asth-
matics have impaired perception of dyspnea,15 in
this study, Poor Perceivers were significantly older
than were Fair Perceivers, and the perception of
resistive load was negatively correlated with age.
However, because the degree of improvement in
the perception of load following asthma treatment
was positively related to age, we can, at the least,
expect a beneficial effect of anti-asthma treatment
on dyspnea perception, even in elderly patients.
The levels of blood eosinophils and total IgE
functioned as factors negatively affecting the
treatment of impaired dyspnea perception. Airway
hyperresponsiveness, a characteristic feature of
asthma, is related to eosinophilia16 and allergic
responses.17,18 Thus, underlying severe asthma,
neurotoxins released by activated eosinophils, and
temporal adaptation of sensory nerves in the
airways because of the prolonged stimulation byinflammatory mediators may impair dyspnea per-
ception3,11 and appear to adversely affect the
efficacy of treatment.
As in our previous report using a short-acting
inhaled b2 agonist,
4 the change in the HR-induced
DBorg score was not related to the change in FEV1
after treatment. Thus, the increased perception of
dyspnea following treatment with anti-asthma
drugs may not simply be caused by the amelioration
of airflow limitation. Suppression of eosinophilic
airway inflammation, with a consequent removal of
the factors adversely affecting the perception of
dyspnea, must be the most important mechanism of
the therapeutic effects on dyspnea perception.
Additionally, the central stimulatory action of
theophylline19 and regular monitoring of the airflow
rate,20 both of which were administered in all of
the patients examined here, would also increase
the perception of dyspnea.
Although anti-asthma treatments increased load-
induced dyspnea in patients with impaired percep-
tion, baseline dyspnea decreased as the lung
function was improved by treatment. This decrease
in dyspnea following treatment also seems to be
caused by more than the amelioration of airflow
limitation. Indeed, the perception of dyspnea is
subjective. Even without further concomitant im-
provement in lung function, the sense of relief
associated with the initial increase in FEV1 provided
by effective anti-asthma therapy and the decrease
in dyspnea could be continued. In addition, this
sense of relief may cause the gradual decrease in
the Borg score at HR associated with a decrease in
the baseline Borg score observed in the Fair
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the signs and symptoms of asthma do not accu-
rately reflect alterations in the pulmonary me-
chanics.21
Our findings suggest that anti-asthma treatments
decrease dyspnea even without a concomitant
improvement in lung function but correct an
impaired perception of dyspnea in patients with
acute asthma, and that age and allergy influence
the effect of treatments on impaired perception.Acknowledgments
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